E-LIB Suche - Ergebnisse für: Cascinu, S.

1

86P Artificial intelligence tools to predict early progress..:

Ogliari, F.R. ; Traverso, A. ; Barbieri, S....
ESMO Open. 9 (2024) - p. 102665 , 2024

Link: https://doi.org/10.1016/..

2

184P Lenvatinib (L) versus sorafenib (S) second-line therap..:

Persano, M. ; Rimini, M. ; Foti, S....
Annals of Oncology. 35 (2024) - p. S83 , 2024

Link: https://doi.org/10.1016/..

3

105P Thoracic radiotherapy and tyrosine kinase inhibitors a..:

Nuccio, A. ; Torrisi, M. ; Ogliari, F.R....
ESMO Open. 8 (2023) 1 - p. 100963 , 2023

Link: https://doi.org/10.1016/..

4

T.02.1 DELPHI INITIATIVE FOR EARLY-ONSET COLORECTAL CANCER ..:

Cavestro, G.M. ; Mannucci, A. ; Balaguer, F....
Digestive and Liver Disease. 55 (2023) - p. S139-S140 , 2023

Link: https://doi.org/10.1016/..

5

PO-1355 Impact of lymphopenia in patients with esophageal c..:

SLIM, N. ; Chissotti, C. ; Passoni, P....
Radiotherapy and Oncology. 182 (2023) - p. S1086-S1087 , 2023

Link: https://doi.org/10.1016/..

6

PO-1308 Thoracic Radiotherapy and Tyrosine Kinase Inhibitor..:

Nuccio, A. ; Torrisi, M. ; Ogliari, F.R....
Radiotherapy and Oncology. 182 (2023) - p. S1048 , 2023

Link: https://doi.org/10.1016/..

7

88P Adverse events (AEs) as potential predictive factors of..:

Persano, M. ; Rimini, M. ; Tada, T....
Immuno-Oncology and Technology. 20 (2023) - p. 100560 , 2023

Link: https://doi.org/10.1016/..

8

78P Clinical outcomes with atezolizumab plus bevacizumab (A..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology. 16 (2022) - p. 100182 , 2022

Link: https://doi.org/10.1016/..

9

108P Role of the prognostic nutritional index in predicting..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology. 16 (2022) - p. 100212 , 2022

Link: https://doi.org/10.1016/..

10

111P Identification of atezolizumab plus bevacizumab progno..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology. 16 (2022) - p. 100215 , 2022

Link: https://doi.org/10.1016/..

11

179: EARLY PREDICTION OF PATHOLOGICAL RESPONSE TO NEOADJUVA..:

Palumbo, D ; Fiorino, C ; Mori, M...
Diseases of the Esophagus. 35 (2022) Supplement_1 - p. , 2022

Link: https://doi.org/10.1093/..

12

MO-0880 Quantifying individual dose relationships for pCR i..:

Cicchetti, A. ; Passoni, P. ; Broggi, S....
Radiotherapy and Oncology. 170 (2022) - p. S768-S769 , 2022

Link: https://doi.org/10.1016/..

13

67P Real-world data for atezolizumab plus bevacizumab in un..:

Persano, M. ; Rimini, M. ; Tada, T....
Immuno-Oncology and Technology. 16 (2022) - p. 100172 , 2022

Link: https://doi.org/10.1016/..

14

65P Atezolizumab plus bevacizumab versus lenvatinib for unr..:

Rimini, M. ; Casadei Gardini, A. ; Persano, M....
Immuno-Oncology and Technology. 16 (2022) - p. 100170 , 2022

Link: https://doi.org/10.1016/..

15

PO-1214 Toxicity profile of adjuvant hypofractionated Image..:

SLIM, N. ; Pacifico, P. ; Passoni, P....
Radiotherapy and Oncology. 161 (2021) - p. S1005-S1006 , 2021

Link: https://doi.org/10.1016/..